Representatives Donna Shalala and Matt Gaetz have introduced a bipartisan bill that seeks to reclassify cannabis at a federal level in order to enhance analysis efforts.

The Expanding Cannabis Study and Information and facts Act seeks to move marijuana from Schedule I to Schedule III of the Controlled Substances Act.

Shalala and Gaetz think that its present classification prevents scientists from correctly examining its added benefits and effects. Moving it down to Schedule III would make it less difficult for researchers to study cannabis and lessen the conflict involving the federal government and the 33 states that have legalized healthcare cannabis use.

“By rescheduling cannabis and directing our national analysis infrastructure to study and gather information on how it impacts well being outcomes, we are not only bringing federal cannabis policy into the 21st century, but we’re also guaranteeing that we do so safely,” stated Shalala, a Democrat.

She previously served as Well being and Human Solutions secretary for the duration of the Clinton administration. At the time, she was a prominent critic of cannabis liberalization, but she has considering that changed her tune and stated that decriminalizing marijuana really should be regarded a moral crucial.

Gaetz is a Republican and he has regularly efforts to reclassify cannabis in the previous. He desires to enhance, expedite and streamline cannabis analysis in order to create a much better scientific understanding of its quick and extended-term added benefits and effects of cannabis on human well being.

The Expanding Cannabis Study and Information and facts Act is identical companion legislation to a bill filed by Sen. Dick Durbin in July.

It would create a national cannabis analysis agenda, instruct the U.S. Division of Well being and Human Solutions to gather information on the well being impacts of cannabis and establish a National Institutes of Well being “Centers of Excellence” analysis designation, along with reclassifying cannabis as a Schedule III controlled substance.

It follows news of the DEA unveiling plans to raise the quantity of marijuana legally developed for analysis purposes in the U.S. by 30% in 2020.